Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Nin, Dawn Sijin ^a,b   Kok, Wai Kay ^a   Li, Feng ^a   Takahashi, Shinichiro ^d   Chng, Wee Joo ^a,b,c   Khan, Matiullah ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; GENISTEIN; NUCLEAR RECEPTOR COREPRESSOR; FLT3 PROTEIN, HUMAN; NCOR1 PROTEIN, HUMAN; RECEPTOR INTERACTING PROTEIN 140;

ACUTE MONOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; PROMOTER REGION; PROTEIN MISFOLDING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; NUCLEAR RECEPTOR CO-REPRESSOR 1; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84859709824     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034501     Document Type: Article

References (37)

1. Haferlach T, Schoch C, Schnittger S, Kern W, Löffler H, et al. (2002) Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 118: 426-431.
2. Villeneuve P, Kima DT, Xub W, Brandwein J, Chang H, (2008) The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes. Leukemia Res 32: 269-273.
3. Balgobind BrianV, Raimondi SC, Harbott J, Zimmerman M, Alonzo TA, et al. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114: 2489-2496.
4. Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM, (1998) Hematological malignancies with t(9;11)(p21-22;q23): a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia 12: 792-800.
5. Karauzum SB, Bilgen T, Karadogan I, Yakut S, Cetin Z, et al. (2005) Novel Cytogenetic findings revealed by conventional cytogentic and FISH analyses in Leukemia patients. Exp Oncol 27: 229-232.
6. Heinzel T, Lavinsky RM, Mullen TM, Söderstrom M, Laherty CD, et al. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387: 43-48.
7. Hörlein A, Näär A, Heinzel T, Torchia J, Gloss B, et al. (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377: 397-404.
8. Laherty C, Billin A, Lavinsky R, et al. (1998) SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell 2: 33-42.
9. Laherty CD, Yang WM, Sun JM, et al. (1997) Histone deacetylase associated with the mSin3 corepressor mediate Mad transcriptional repression. Cell 89: 349-356.
10. Nomura T, Khan MM, Kual SC, et al. (1999) Ski is a component of the Histone Deacetylase Complex required for Transcriptional Repression. Mediated by Mad and Thyroid hormone receptor. Genes Dev 13: 412-423.
11. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, et al. (2001) Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 7: 1233-1243.
12. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, et al. (2001) PML-RARalpha alleviates the transcriptional repression mediated by tumour suppressor Rb. J Biol Chem 276: 43491-43494.
13. Khan MM, Nomura T, Chiba T, Tanaka K, Yoshida H, et al. (2004) The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. J Biol Chem 279: 11814-11824.
14. Ng APP, Fong JH, Nin DS, Hirpara JL, Asou N, et al. (2006) Cleavage of misfolded nuclear receptor corepressor confers resistance to unfolded protein response-induced apoptosis. Cancer Research 66: 9903-9912.
15. Ng APP, Nin DS, Fong JH, Venkataraman D, Chen CS, et al. (2007) Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. Molecular Cancer Therapeutics 6: 2240-2248.
16. Zhang D, Cho E, Wong J, (2007) A critical role for the co-repressor N-CoR in erythroid differentiation and heme synthesis. Cell Res 17: 804.
17. Jepsen K, Hermanson O, Onami T, (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102: 753.
18. Agnès F, Shamoon B, Dina C, Rosnet O, Birnbaum D, et al. (1994) Genomic structure of the downstream part of the human FLT3 gene:exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene 145: 283-288.
19. Moore MA, Dorn DC, Schuringa JJ, et al. (2007) Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol 35: 105-116.
20. Parcells BW, Ikeda AK, Simms-Waldrip T, et al. (2006) FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24: 1174-1184.
21. Muench MO, Roncarolo MG, Menon S, et al. (1995) FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 85: 963-972.
22. Carow CE, Kim E, Hawkins AL, Webb HD, Griffin CA, et al. (1995) Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12->q13. Cytogenet Cell Genet 70: 255-257.
23. Birg F, Courcoul M, Rosnet O, Bardin F, Pébusque MJ, et al. (1992) The expression of FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 80: 2584-2593.
24. Birg F, Rosnet O, Carbuccia N, Birnbaum D, (1994) The expression of FMS, KIT and FLT3 in hematopoietic malignancies. Leuk Lymphoma 13: 223-227.
25. Gililand D, (2003) FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk adapted therapy with FLT3 inhibitors. Best Pract Res Clin Haematol 16: 409-417.
26. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, et al. (2003) Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-183.
27. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, et al. (2008) MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 22: 66-77.
28. Lilakos K, Viniou NA, Mavrogianni D, Vassilakopoulos TP, Dimopoulou MN, et al. (2006) FLT3 Overexpression in Acute Promyelocytic Leukemia Patients without Detectable FLT3-ITD or Codon 835-836 Mutations: A Pilot Study. Anticancer Res 26: 1201-1207.
29. Stubbs MC, Armstrong SA, (2007) FLT3 as a therapeutic target in childhood acute leukemia. Curr Drug Targets 8: 703-714.
30. Beau MML, Davis EM, Patel B, Phan VT, Sohal J, et al. (2003) Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia. Blood 102: 1072-1074.
31. Iwasaki H, Mizuno S, Arinobu Y, Ozawa H, Mori Y, et al. (2006) The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev 20: 3010-3021.
32. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, et al. (2008) Human Flt3 is expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor stages to maintain cell survival. J Immunol 180: 7358-7367.
33. Birg F, Courcoul M, Rosnet O, Bardin F, Pébusque MJ, et al. (1992) The expression of FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 80: 2584-2593.
34. Carow CE, Kim E, Hawkins AL, Webb HD, Griffin CA, et al. (1995) Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12->q13. Cytogenet Cell Genet 70: 255-257.
35. Aleskog A, Höglund M, Pettersson J, Hermansson M, Larsson R, et al. (2005) In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia. Leuk Res 29: 1079-1081.
36. Kindler T, Lipka DB, Fischer T, (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116: 5089-5102.
37. Ng APP, Chng WJ, Khan M, (2011) Curcumin Sensitizes Acute Promyelocytic Leukemia Cells to Unfolded Protein Response-induced Apoptosis by Blocking the Loss of Misfolded N-CoR Protein. Mol Caner Res 9: 878-888.